One-year recovery from breast cancer: Importance of tumor and treatment-related factors, resilience, and sociodemographic factors for health-related quality of life

Katarina Veličković, Carl A K Borrebaeck, Pär-Ola Bendahl, Cecilia Hegardt, Per Johnsson, Corinna Richter, Lisa Rydén, Ingalill Rahm Hallberg, Katarina Veličković, Carl A K Borrebaeck, Pär-Ola Bendahl, Cecilia Hegardt, Per Johnsson, Corinna Richter, Lisa Rydén, Ingalill Rahm Hallberg

Abstract

Aim: This study investigated the changes in health-related quality of life from diagnosis to 1 year after diagnosis in breast cancer (BC) patients and the influence of clinical, psychological, and sociodemographic variables. An additional aim was to explore the mediating and moderating effects of resilience on changes in health-related quality of life.

Methods: A longitudinal population-based study was conducted in southern Sweden. Newly diagnosed BC patients filled in measures of health-related quality of life, resilience, and sociodemographic variables at diagnosis (N = 980) and 1 year post-diagnosis (N = 780). Clinical variables were extracted from the Swedish national breast cancer quality registry. Mixed-model analyses were performed.

Results: Most health-related quality of life outcomes declined from diagnosis to 1 year post-diagnosis. Role limitations due to emotional problems remained the same, whereas mental health improved. Lower health-related quality of life outcomes were associated with symptomatic detection and axillary dissection. Patients with a higher TNM stage and histologic grade and estrogen receptor (ER)-negative and human epidermal growth factor 2 (HER2)-positive status, who received chemotherapy, antibody therapy, or bisphosphonate therapy, had a steeper decline in outcomes. Changes in resilience were positively associated with all outcomes but did not mediate or moderate changes in any. Resilience at baseline moderated changes in bodily pain, vitality, and mental health, with higher baseline resilience being associated with a steeper decline, possibly due to floor or ceiling effects. Patients with lower socioeconomic status, educational level, and older age had a lower health-related quality of life.

Conclusion: Physical health-related quality of life among breast cancer patients declined 1 year post-diagnosis, whereas mental health-related quality of life improved. Low resilient patients may be especially vulnerable at diagnosis. Biopsychosocial assessment at diagnosis can help identify patients who may require additional support. A multidimensional treatment plan should be started early to help overcome the problems in everyday activities.

Keywords: biopsychosocial (BPS) model; breast cancer; breast cancer treatment; health-related quality of life (HRQL); longitudinal study; multidisciplinary; psychological resilience; tumor characteristics.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Veličković, Borrebaeck, Bendahl, Hegardt, Johnsson, Richter, Rydén and Hallberg.

Figures

Figure 1
Figure 1
Flow diagram of the study cohort.
Figure 2
Figure 2
Simple slopes of the moderating effect of menstrual status on changes in bodily pain (A) and PCS (B); TNM stage on changes in bodily pain (C); histologic grade on changes in physical role limitations (D) and PCS (E). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes for TNM stage and histologic grade are adjusted for age, radiotherapy, and systemic therapy. PCS, physical health component score.
Figure 3
Figure 3
Simple slopes of the moderating effect of ER status on changes in role limitations—physical (A) and PCS (B); HER2 status on changes in social functioning (C), role limitations—emotional (D), and MCS (E). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes are adjusted for age, radiotherapy, and systemic therapy. PCS, physical health component score; MCS, mental health component score; HER2, human epidermal growth factor 2.
Figure 4
Figure 4
Simple slopes of the moderating effect of type of surgery on changes in bodily pain (A), social functioning (B), and PCS (C). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes are adjusted for age. PCS, physical health component score.
Figure 5
Figure 5
Simple slopes of the moderating effect of chemotherapy on changes in physical functioning (A), Role limitations due to physical problems (B), bodily pain (C), vitality (D), and PCS (E). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes are adjusted for age. PCS, physical health component score.
Figure 6
Figure 6
Simple slopes of the moderating effect of antibody therapy on changes in vitality (A), role limitations—emotional (B), and MCS (C). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes are adjusted for age. MCS, mental health component score.
Figure 7
Figure 7
Simple slopes of the moderating effect of bisphosphonate therapy on changes in physical functioning (A), role limitations—physical (B), bodily pain (C), and PCS (D). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. Simple slopes are adjusted for age. PCS, physical health component score.
Figure 8
Figure 8
Simple slopes of the moderating effect of baseline resilience on changes in bodily pain (A), vitality (B), mental health (C), and MCS (D). Higher scores on outcome variables indicate better functioning. Error bars show standard errors. MCS, mental health component score.

References

    1. Swedish Cancer Registry . (2018). Available at: (Accessed December 12, 2021).
    1. Xu S, Liu Y, Zhang T, Zheng J, Lin W, Cai J. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: Results from the global burden of disease study 2019. Front Oncol (2021) 11:689562. doi: 10.3389/fonc.2021.689562
    1. Molina Y, Yi JC, Martinez-Gutierrez J, Reding KW, Yi-Frazier JP, Rosenberg AR. Resilience among patients across the cancer continuum: diverse perspectives. Clin J Oncol Nurs (2014) 18:93–101. doi: 10.1188/14.CJON.93-101
    1. Alonso Y. The biopsychosocial model in medical research: The evolution of the health concept over the last two decades. Patient Educ Couns (2004) 53:239–44. doi: 10.1016/S0738-3991(03)00146-0
    1. Invernizzi M, de Sire A, Lippi L, Venetis K, Sajjadi E, Gimigliano F, et al. . Impact of rehabilitation on breast cancer related fatigue: A pilot study. Front Oncolog (2020) 10:556718. doi: 10.3389/fonc.2020.556718
    1. Li L, Wang R, Zhang A, Wang L, Ge Q, Liu Y. Evidence on efficacy and safety of Chinese medicines combined western medicines treatment for breast cancer with endocrine therapy. Front Oncolog (2021) 11:661925. doi: 10.3389/fonc.2021.661925
    1. Zhang Y, Sun Y, Li D, Liu X, Fang C, Yang C. Acupuncture for breast cancer: A systematic review and meta-analysis of patient-reported outcomes. Front Oncol (2021) 11:646315. doi: 10.3389/fonc.2021.6463158
    1. Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, et al. . A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat (2003) 77:285–93. doi: 10.1023/a:1021853302033
    1. van Gestel YRBM, Voogd AC, Vingerhoets AJJM, Mols F, Nieuwenhuijzen GAP, Repelaer van Driel OJ, et al. . A comparison of quality of life, disease impact and risk perception in women with invasive breast bancer and ductal carcinoma in situ. Eur J Cancer (2007) 43:549–56. doi: 10.1016/j.ejca.2006.10.010
    1. Syrowatka A, Motulsky A, Kurteva S, Hanley JA, Dixon WG, Meguerditchian AN, et al. . Predictors of distress in female breast cancer survivors: A systematic review. Breast Cancer Res Treat (2016) 165:229–45. doi: 10.1007/s10549-017-4290-9
    1. Kim JM, Jang JE, Stewart R, Kim SY, Kim SW, Kang HJ, et al. . Determinants of suicidal ideation in patients with breast cancer. Psycho-Oncology (2013) 22:2848–56. doi: 10.1002./pon.3367
    1. Buijs C, de Vries EGE, Mourits MJE, Willemse PHB. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev (2007) 34:640–55. doi: 10.1016/j.ctrv.2008.04.001
    1. Jamil K, Kumar K, Fatima SH, Rabbani S, Kumar R, Perimi R. Clinical studies on hormonal status in breast cancer and its impact on quality of life (QOL). J Cancer Sci Ther (2009) 1:83–9. doi: 10.4172/1948-5956.1000013
    1. Ross JS, Slodowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 14:320–68. doi: 10.1634/theoncologist.2008-0230
    1. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early-stage breast cancer. Breast Cancer Res Treat (2013) 137:449–55. doi: 10.1007/s10549-012-2366-0
    1. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NA, Gelmon KA, et al. . Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Onc (2019) 37:423–38. doi: 10.1200/JCO.18.01160
    1. von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, et al. . Trastuzumab emtansine for residual invasive HER2-positive breast cancer. NEJM (2019) 380:617–28. doi: 10.1056/NEJMoa1814017
    1. Tai CJ, Pan CK, Chen CS, Hung CS, Wu CH, Chiou HY. Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer. Asian Pac J Cancer Prev (2013) 14:1981–4. doi: 10.7314/apjcp.2013.14.3.1981
    1. American Society of Clinical Oncology . ASCO gudelines (2018). Available at: (Accessed January 13, 2022).
    1. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res (2008) 27:32. doi: 10.1186/1756-9966-27-32
    1. Ng ET, Ang RZ, Tran BX, Ho CS, Zhang Z, Tan W, et al. . Comparing quality of life in breast cancer patients who underwent mastectomy versus breast-conserving surgery: A meta-analysis. Int J Environ Res Public Health (2019) 16:4970. doi: 10.3390/ijerph16244970
    1. Zehra S, Doyle F, Barry M. Health-related quality of life following breast reconstruction compared to total mastectomy and breast-conserving surgery among breast cancer survivors: A systematic review and meta-analysis. Breast Cancer (2020) 27:534–66. doi: 10.1007/s12282-020-01076-1
    1. Brar P, Jain S, Singh I. Complications of axillary lymph node dissection in treatment of early breast cancer: A comparison of MRM and BCS. Indian J Surg Oncol (2011) 2:126–32. doi: 10.1007/s13193-011-0078-2
    1. Galalae RM, Michel J, Siebmann JU, Küchler T, Eilf K, Kimmig B. Significant negative impact of adjuvant chemotherapy on health-related quality of life (HR-QOL) in women with breast cancer treated by conserving surgery and postoperative 3-d radiotherapy. A Prospective Measurement Strahlenther Onkol (2005) 181:645–51. doi: 10.1007/s00066-005-1403-x
    1. Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther (2018) 18:1101–12. doi: 10.1080/14737140.2018.1520096
    1. Willems A, Gauger K, Henrichs C, Hardbeck N. Antibody therapy for breast cancer. Anticancer Res (2005) 25:1483–9.
    1. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discovery (2010) 9:325–38. doi: 10.1038/nrd3003
    1. Jackson C, Freeman ALJ, Szlamka Z, Spiegelhalter DJ. The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis. PloS One (2021) 16:e0246441. doi: 10.1371/journal.pone.0246441
    1. Fletcher D, Sarkar M. Psychological resilience: A review and critique of definitions, concepts and theory. Eur Psychol (2013) 18:12–23. doi: 10.1027/1016-9040/a000124
    1. Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci (2009) 10:446–57. doi: 10.1038/nrn2649
    1. Gillespie BM, Chaboyer W, Wallis M. The influence of personal characteristics on the resilience of operating room nurses: A predictor study. Int J Nurs Stud (2009) 46:968–76. doi: 10.1016/j.ijnurstu.2007.08.006
    1. Kenne Sarenmalm E, Browall M, Persson LO, Fall-Dickson J, Gaston-Johansson F. Relationship of sense of coherence to stressful events, coping strategies, health status, and quality of life in women with breast cancer. Psycho-Oncology (2013) 22:20–7. doi: 10.1002/pon.2053
    1. Lam WW, Bonanno GA, Mancini AD, Ho S, Chan M, Hung WK, et al. . Trajectories of psychological distress among chinese women diagnosed with breast cancer. Psycho-Oncology (2010) 19:1044–51. doi: 10.1002/pon.1658
    1. Carver CS, Smith RG, Petronis VM, Antoni MH. Quality of life among long-term survivors of breast cancer: Different types of antecedents predict different classes of outcomes. Psycho-Oncology (2006) 15:749–58. doi: 10.1002/pon.1006
    1. Harms CA, Cohen L, Pooley JA, Chambers SK, Galvao DA, Newton RU. Quality of life and psychological distress in cancer survivors: The role of psycho-social resources for resilience. Psychooncology (2018) 28:271–7. doi: 10.1002/pon.4934
    1. Ristevska-Dimitrovska G, Filov I, Rajchanovska D, Stefanovski P, Dejanova B. Resilience and quality of life in breast cancer patients. Open Access Maced J Med Sci (2015) 3:727–31. doi: 10.3889/oamjms.2015.128
    1. Mohlin Å, Bendahl P, Hegardt C, Richter C, Rahm Hallberg I, Ryden L. Psychological resilience and health-related quality of life in 418 swedish women with primary breast cancer: Results from a prospective longitudinal study. Cancers (Basel) (2021) 13:2233. doi: 10.3390/cancers13092233
    1. Downes BJ, Miller F, Barnett J, Glaister A, Ellemor H. How do we know about resilience? an analysis of empirical research on resilience, and implications for interdisciplinary praxis. Environ Res Lett (2013) 8:14041. doi: 10.1088/1748-9326/8/1/014041
    1. Rustoen T, Moum T, Wiklund I, Hanestad BR. Quality of life in newly diagnosed cancer patients. J Adv Nurs (1999) 29:490–8. doi: 10.1046/j.1365-2648.1999.00912.x
    1. Suppli NP, Johansen C, Christensen J, Kessing LV, Kroman N, Dalton SO. Increased risk for depression after breast cancer: A nationwide population-based cohort study of associated factors in Denmark, 1998-2011. J Clin Oncol (2014) 32:3831–9. doi: 10.1200/JCO.2013.54.0419
    1. Lan B, Jiang S, Li T, Sun X, Ma F. Depression, anxiety, and their associated factors among chinese early breast cancer in women under 35 years of age: A cross sectional study. Curr Probl Cancer (2020) 44:100558. doi: 10.1016/j.currproblcancer.2020.100558
    1. Nausheen B, Gidron Y, Peveler R, Moss-Morris R. Social support and cancer progression: A systematic review. J Psychosom Res (2009) 67:403–15. doi: 10.1016/j.jpsychores.2008.12.012
    1. Axelsson U, Rydén L, Johnsson P, Eden P, Mansson J, Hallberg IR, et al. . A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: Study protocol of the SCAN-b resilience study. BMC Cancer (2018) 18:1–7. doi: 10.1186/s12885-018-4669-y
    1. Saal LH, Vallon-Christersson J, Hakkinen J, Hegardt C, Grabau D, Winter C, et al. . The Sweden cancerome analysis network - breast (SCAN-b) initiative: A large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med (2015) 7:20. doi: 10.1186/s13073-015-0131-9
    1. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: A users' manual. Boston, MA: Health Assessment Lab; (1994).
    1. Quality Metric Health Outcomes . PRO CoRE software (Version 1.4.7003.15542). [Computer software] (2019). Available at: (Accessed March 15, 2020).
    1. Sullivan M, Karlsson J, Taft C, Ware JE. SF-36 health survey: Swedish manual and interpretation guide). Göteborg: Sahlgrenska Sjukhuset Sektionen för Vårdforskning; (2002).
    1. Regional Cancer Centers . Swedish National quality registry for breast cancer. summary and guidance for the interactive annual report (2019). Available at: (Accessed January 13, 2022).
    1. Connor KM, Davidson JR. Development of a new resilience scale: The connor–Davidson resilience scale (CD-RISC). Depress Anxiety (2003) 18:76–82. doi: 10.1002/da.10113
    1. Luke DA. Multilevel modeling. NP, California: SAGE Publications; (2004). doi: 10.4135/9781412985147
    1. Eekhout I, de Vet HCW, Twisk JWR, Brand JPL, de Boer MR, Heymans MW. Missing data in a multi-item instrument were best handled by multiple imputation at the item score level. J Clin Epidem (2014) 67:335–42. doi: 10.1016/j.jclinepi.2013.09.009
    1. Sedgwick P. Multiple hypothesis testing and bonferroni’s correction. BMJ (2014) 349:1–3. doi: 10.1136/bmj.g6284
    1. RStudio Team . RStudio: Integrated development for r (Version 1.1.456) [Computer software] (2018). Boston, MA. Available at: (Accessed February 23, 2020).
    1. The jamovi project . Jamovi (Version 1.6) [Computer software] (2021). Available at: (Accessed March 13, 2021).
    1. Toscano A, Blanchin M, Bourdon M, Antignac AB, Sebille V. Longitudinal associations between coping strategies, locus of control and health-related quality of life in patients with breast cancer or melanoma. Qual Life Res (2020) 29:1271–9. doi: 10.1007/s11136-019-02401-8
    1. Trudel JG, Leduc N, Dumont S. Perceived communication between physicians and breast cancer patients as a predicting factor of patients' health-related quality of life: A longitudinal analysis. Pscyho-oncology (2013) 23:531–8. doi: 10.1002/pon.3442
    1. Boini S, Briancon S, Guillemin F, Galan P, Hercberg S. Impact of cancer occurrence on health-related quality of life: A longitudinal pre-post assessment. Health Qual Life Outcomes (2004) 2:4. doi: 10.1186/1477-7525-2-4
    1. Morse JM, Pooler C, Vann-Ward T, Maddox LJ, Olausson JM, Roche-Dean M, et al. . Awaiting diagnosis of breast cancer: Strategies of enduring for preserving self. Onc Nurs Forum (2014) 41:350–9. doi: 10.1188/14.ONF.350-359
    1. Gibbons A, Groarke A, Curtis R, Groarke J. The effect of mode of detection of breast cancer on stress and distress. Psycho-oncology (2017) 26:787–92. doi: 10.1002/pon.4227
    1. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-b. Breast Cancer Res Treat (1999) 55:189–99. doi: 10.1023/a:1006263818115
    1. Lundgren C, Lindman H, Rolander B, Ekholm M. Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish prescribed drug register. Acta Oncol (2018) 57:935–40. doi: 10.1080/0284186X.2018.1442932
    1. Fallowfield L, Cella D, Cuzick D, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol (2004) 22:4261–71. doi: 10.1200/JCO.2004.08.029
    1. Fuzesi S, Becetti K, Klassen AF, Gemignani ML, Pusic AL. Expectations of breast-conserving therapy: A qualitative study. J Pat-Rep Outcomes (2019) 3:73. doi: 10.1186/s41687-019-0167-5
    1. Gu J, Groot G, Holtslander L, Engler-Stringer R. Understanding women’s choice of mastectomy versus breast conserving therapy in early-stage breast cancer. Clin Med Insights: Oncol (2017) 11:1–7. doi: 10.1177/1179554917691266
    1. Hussain SK, Altieri A, Sundquist J, Hemminki K. Influence of education level on breast cancer risk and survival in sweden between 1990 and 2004. Int J Cancer (2008) 122:165–9. doi: 10.1002/ijc.23007
    1. Mehnert S, Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res (2008) 64:383–91. doi: 10.1016/j.jpsychores.2007.12.005
    1. Beckman A, Merlo J, Lynch JW, Gerdtham U-G, Lindström M, Litham T. Country of birth, socioeconomic position, and healthcare expenditure: A multilevel analysis of malmö, Sweden. J Epidemiol Community Health (2004) 58:145–9. doi: 10.1136/jech.58.2.145

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere